Content Navigation
( All
None )
Target General Information |
Top |
Target ID |
T17279 |
Target Info
|
Target Name |
RET S891A mutant (RET S891A) |
Synonyms |
RET51 S891A mutant; Proto-oncogene tyrosine-protein kinase receptor Ret S891A mutant; Proto-oncogene c-Ret S891A mutant; PTC S891A mutant; Cadherin family member 12 S891A mutant; CDHR16 S891A mutant; CDHF12 S891A mutant |
Target Type |
Patented-recorded Target |
Gene Name |
RET |
Biochemical Class |
Kinase |
UniProt ID |
|
Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2014050781 |
Title |
Ret Inhibitor. |
Abstract |
A compound represented by general formula (I) (the symbols in the formula are as defined in the description), a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can be used as an agent for the prevention or treatment of disorders including cancers and cancer metastases having mutations in RET. |
Applicant(s) |
Chugai Pharmaceutical Co., Ltd |
Representative Drug(s) |
D0O9JD |
Drug Info
|
IC50 = 8.3 nM |
[1] |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20140272958 |
Title |
Ret Inhibitor. |
Applicant(s) |
Chugai Pharmaceutical |
Representative Drug(s) |
D0O9JD |
Drug Info
|
IC50 = 8.3 nM |
[1] |
References |
Top |
REF 1 |
RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.